Durvalumab Treatment Regimen Reduces Risk of Disease Progression, Death in Patients With HCC

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

Related Keywords

San Francisco ,California ,United States ,American ,Bruno Sangro ,Susan Galbraith ,Genentech ,Astrazeneca ,Liver Unit ,Universidad De Navarra ,